Reporting from: – European Society for Medical Oncology Congress, October 29-November 10, 2004, Vienna – Journal of Clinical Oncology – New England Journal of Medicine – Lancet
Reporting from:
– European Society for Medical Oncology Congress, October 29-November 10, 2004, Vienna
– Journal of Clinical Oncology
– New England Journal of Medicine
– Lancet
In this edition:
The ESMO conference in Vienna heard news from Charles Butts that patients with advanced lung cancer have responded to a vaccine.
Diane Harper describes from her article the protection a vaccine has given against human papillomavirus types 16 and 18, raising hopes that widespread prevention of cervical cancer could be undertaken by immunization.
Daniel Haller told delegates at ESMO that his phase III study shows that the IROX combination of irinotecan plus oxaliplatin is superior to irinotecan monotherapy and does not add toxicity.
George Canellos reflects on the immune processes holding follicular lymphoma cells in check as revealed by a New England Journal of Medicine article looking at gene profiles and their prognostic implications for this variable disease.
…